国际妇产科学杂志

国际妇产科学杂志 ›› 2014, Vol. 41 ›› Issue (3): 236-239.

• 综述 • 上一篇    下一篇

卵巢癌的DNA甲基化研究进展

丁一，龚晓明   

  1. 200020 上海，同济大学附属第一妇婴保健院
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2014-06-15 发布日期:2014-06-15
  • 通讯作者: 龚晓明

Progress of DNA Methylation Changes in Ovarian Cancer

DING Yi，GONG Xiao-ming   

  1. The First Maternity and Infant Hospital Affiliated to Tongji University，Shanghai 200020，China
  • Received:1900-01-01 Revised:1900-01-01 Published:2014-06-15 Online:2014-06-15
  • Contact: GONG Xiao-ming

PDF (PC)

5136

摘要： 卵巢癌是常见的妇科恶性肿瘤，但由于缺乏早期的诊断手段，其病死率居于妇科肿瘤首位。DNA甲基化是最早发现的表观遗传学改变。RAS相关领域家族基因1（RASSF1A）、乳腺癌易感基因1（BRCA1）和hMLH1等基因的甲基化在卵巢癌的发生、发展中发挥重要作用，通过对这些基因的甲基化检测，可以有助于对卵巢癌的早期诊断。然而，一些基因的甲基化，如hMLH1，可能降低癌细胞对化疗的敏感性。去甲基化药物则可以使得这些甲基化基因发生去甲基化，从而改善化疗效果和患者的预后。综述对卵巢癌主要相关基因的甲基化研究的最新进展。

关键词: DNA甲基化, 卵巢肿瘤, 癌, 诊断, 治疗

Abstract: Ovarian cancers are the most common gynecological neoplasms，which has the highest mortality rate of cancers of the reproductive organs，because of lack of effective early diagnostic tool. DNA methylation is the first epigenetic changes discovered by human. Methlation of RASSF1A、BRCA1 and hMLH1 genes play an important role in the development of ovarian cancers. Detection of these genes could help early cancer diagnosis. However, some DNA methylation, like hMLH1, decline the sensitivity of chemotherapy drugs to tumor cells. Demethylation drugs which can reexpress those genes may improve the effect of chemotherapy and prognosis. In this review，we have summarized the newest researchs of DNA methylation changes in ovarian cancer.

Key words: DNA methylation, Ovarian neoplasms, Carcinoma, Diagnosis, Therapy